Treating drug-resistant tuberculosis in a low-intensity chronic conflict setting in India
Introduction The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Médecins Sans Frontières (MSF) has been providing primary health care services in the conflict-affected region along the An...
Saved in:
| Published in | Conflict and health Vol. 8; no. 1; p. 25 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
01.12.2014
BioMed Central Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1752-1505 1752-1505 |
| DOI | 10.1186/1752-1505-8-25 |
Cover
| Abstract | Introduction
The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Médecins Sans Frontières (MSF) has been providing primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011, treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a low-intensity conflict setting in India.
Case description
A total of thirteen patients were diagnosed with drug-resistant TB (DR-TB) between January 2011 and October 2013. An innovative treatment model was developed which delegated responsibility to non-TB clinicians, including primary-care nurses and nurse-aids who were remotely supported by a TB-specialist from the MSF DR-TB project in Mumbai. Individualised regimens were designed for each patient based on WHO guidelines. Of these 13 patients, 10 patients had an outcome, of whom seven (70%) patients were cured. One patient became lost to follow-up prior to treatment initiation, one patient died prior to starting treatment and one patient refused treatment. Three patients were on-treatment, were clinically improving and were culture-negative at the end of their intensive phase of treatment.
Discussion and evaluation
Drug-resistant tuberculosis diagnosis and treatment is a highly specialised and technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to follow-up in patients remains a programmatic challenge and community involvement may play a key role.
Conclusion
Managing DR-TB in a primary health care programme is feasible in a low-conflict setting with an appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered to further simplify treatment delivery and allow for scale-up when needed. |
|---|---|
| AbstractList | Introduction
The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Médecins Sans Frontières (MSF) has been providing primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011, treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a low-intensity conflict setting in India.
Case description
A total of thirteen patients were diagnosed with drug-resistant TB (DR-TB) between January 2011 and October 2013. An innovative treatment model was developed which delegated responsibility to non-TB clinicians, including primary-care nurses and nurse-aids who were remotely supported by a TB-specialist from the MSF DR-TB project in Mumbai. Individualised regimens were designed for each patient based on WHO guidelines. Of these 13 patients, 10 patients had an outcome, of whom seven (70%) patients were cured. One patient became lost to follow-up prior to treatment initiation, one patient died prior to starting treatment and one patient refused treatment. Three patients were on-treatment, were clinically improving and were culture-negative at the end of their intensive phase of treatment.
Discussion and evaluation
Drug-resistant tuberculosis diagnosis and treatment is a highly specialised and technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to follow-up in patients remains a programmatic challenge and community involvement may play a key role.
Conclusion
Managing DR-TB in a primary health care programme is feasible in a low-conflict setting with an appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered to further simplify treatment delivery and allow for scale-up when needed. Introduction The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Mñdecins Sans Frontières (MSF) has been providing primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011, treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a low-intensity conflict setting in India. Case description A total of thirteen patients were diagnosed with drug-resistant TB (DR-TB) between January 2011 and October 2013. An innovative treatment model was developed which delegated responsibility to non-TB clinicians, including primary-care nurses and nurse-aids who were remotely supported by a TB-specialist from the MSF DR-TB project in Mumbai. Individualised regimens were designed for each patient based on WHO guidelines. Of these 13 patients, 10 patients had an outcome, of whom seven (70%) patients were cured. One patient became lost to follow-up prior to treatment initiation, one patient died prior to starting treatment and one patient refused treatment. Three patients were on-treatment, were clinically improving and were culture-negative at the end of their intensive phase of treatment. Discussion and evaluation Drug-resistant tuberculosis diagnosis and treatment is a highly specialised and technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to follow-up in patients remains a programmatic challenge and community involvement may play a key role. Conclusion Managing DR-TB in a primary health care programme is feasible in a low-conflict setting with an appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered to further simplify treatment delivery and allow for scale-up when needed. Keywords: Operational research, Internally displaced populations, Resource-limited settings, Mobile clinic The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Mñdecins Sans Frontières (MSF) has been providing primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011, treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a low-intensity conflict setting in India. Drug-resistant tuberculosis diagnosis and treatment is a highly specialised and technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to follow-up in patients remains a programmatic challenge and community involvement may play a key role. Managing DR-TB in a primary health care programme is feasible in a low-conflict setting with an appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered to further simplify treatment delivery and allow for scale-up when needed. Introduction: The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Medecins Sans Frontieres (MSF) has been providing primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011, treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a low-intensity conflict setting in India. Case description: A total of thirteen patients were diagnosed with drug-resistant TB (DR-TB) between January 2011 and October 2013. An innovative treatment model was developed which delegated responsibility to non-TB clinicians, including primary-care nurses and nurse-aids who were remotely supported by a TB-specialist from the MSF DR-TB project in Mumbai. Individualised regimens were designed for each patient based on WHO guidelines. Of these 13 patients, 10 patients had an outcome, of whom seven (70%) patients were cured. One patient became lost to follow-up prior to treatment initiation, one patient died prior to starting treatment and one patient refused treatment. Three patients were on-treatment, were clinically improving and were culture-negative at the end of their intensive phase of treatment. Discussion and evaluation: Drug-resistant tuberculosis diagnosis and treatment is a highly specialised and technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to follow-up in patients remains a programmatic challenge and community involvement may play a key role. Conclusion: Managing DR-TB in a primary health care programme is feasible in a low-conflict setting with an appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered to further simplify treatment delivery and allow for scale-up when needed. The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Médecins Sans Frontières (MSF) has been providing primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011, treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a low-intensity conflict setting in India.INTRODUCTIONThe eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Médecins Sans Frontières (MSF) has been providing primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011, treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a low-intensity conflict setting in India.A total of thirteen patients were diagnosed with drug-resistant TB (DR-TB) between January 2011 and October 2013. An innovative treatment model was developed which delegated responsibility to non-TB clinicians, including primary-care nurses and nurse-aids who were remotely supported by a TB-specialist from the MSF DR-TB project in Mumbai. Individualised regimens were designed for each patient based on WHO guidelines. Of these 13 patients, 10 patients had an outcome, of whom seven (70%) patients were cured. One patient became lost to follow-up prior to treatment initiation, one patient died prior to starting treatment and one patient refused treatment. Three patients were on-treatment, were clinically improving and were culture-negative at the end of their intensive phase of treatment.CASE DESCRIPTIONA total of thirteen patients were diagnosed with drug-resistant TB (DR-TB) between January 2011 and October 2013. An innovative treatment model was developed which delegated responsibility to non-TB clinicians, including primary-care nurses and nurse-aids who were remotely supported by a TB-specialist from the MSF DR-TB project in Mumbai. Individualised regimens were designed for each patient based on WHO guidelines. Of these 13 patients, 10 patients had an outcome, of whom seven (70%) patients were cured. One patient became lost to follow-up prior to treatment initiation, one patient died prior to starting treatment and one patient refused treatment. Three patients were on-treatment, were clinically improving and were culture-negative at the end of their intensive phase of treatment.Drug-resistant tuberculosis diagnosis and treatment is a highly specialised and technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to follow-up in patients remains a programmatic challenge and community involvement may play a key role.DISCUSSION AND EVALUATIONDrug-resistant tuberculosis diagnosis and treatment is a highly specialised and technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to follow-up in patients remains a programmatic challenge and community involvement may play a key role.Managing DR-TB in a primary health care programme is feasible in a low-conflict setting with an appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered to further simplify treatment delivery and allow for scale-up when needed.CONCLUSIONManaging DR-TB in a primary health care programme is feasible in a low-conflict setting with an appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered to further simplify treatment delivery and allow for scale-up when needed. The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since 2006, Médecins Sans Frontières (MSF) has been providing primary health care services in the conflict-affected region along the Andhra Pradesh-Chhattisgarh border. In 2011, treatment for drug-resistant tuberculosis (DR-TB) was included in the services provided. This report aims to describe MSF experiences of providing treatment to DR-TB patients in a mobile primary health care outpatient clinic, in a low-intensity conflict setting in India. A total of thirteen patients were diagnosed with drug-resistant TB (DR-TB) between January 2011 and October 2013. An innovative treatment model was developed which delegated responsibility to non-TB clinicians, including primary-care nurses and nurse-aids who were remotely supported by a TB-specialist from the MSF DR-TB project in Mumbai. Individualised regimens were designed for each patient based on WHO guidelines. Of these 13 patients, 10 patients had an outcome, of whom seven (70%) patients were cured. One patient became lost to follow-up prior to treatment initiation, one patient died prior to starting treatment and one patient refused treatment. Three patients were on-treatment, were clinically improving and were culture-negative at the end of their intensive phase of treatment. Drug-resistant tuberculosis diagnosis and treatment is a highly specialised and technical subject which requires continued patient follow-up. However, our study demonstrates that it is feasible to manage DR-TB patients in a conflict setting, using a primary-care model with remote expert support. Long-term commitment and sustainability are essential for continued care, even more so in similar conflict settings. Loss to follow-up in patients remains a programmatic challenge and community involvement may play a key role. Managing DR-TB in a primary health care programme is feasible in a low-conflict setting with an appropriate treatment model. Ambulatory strategies and standardised treatment regimens should be considered to further simplify treatment delivery and allow for scale-up when needed. |
| ArticleNumber | 25 |
| Audience | Academic |
| Author | Mansoor, Homa Isaakidis, Petros Armstrong, Edward Das, Mrinalini Babu, Ramesh B |
| Author_xml | – sequence: 1 givenname: Edward surname: Armstrong fullname: Armstrong, Edward organization: Médecins Sans Frontières, Chandni Bungalow – sequence: 2 givenname: Mrinalini surname: Das fullname: Das, Mrinalini organization: Médecins Sans Frontières, Chandni Bungalow – sequence: 3 givenname: Homa surname: Mansoor fullname: Mansoor, Homa organization: Médecins Sans Frontières, Chandni Bungalow – sequence: 4 givenname: Ramesh B surname: Babu fullname: Babu, Ramesh B organization: District TB Control Office (RNTCP) – sequence: 5 givenname: Petros surname: Isaakidis fullname: Isaakidis, Petros email: msfocb-asia-epidemio@brussels.msf.org organization: Médecins Sans Frontières, Chandni Bungalow |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25904975$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks2P1CAYxhuzxv3Qq0fTxMToobPQQikXk83Gj4mb6GE9eCKUvu2wYWAE6jr_vdQZ16lxo-EAefk9D_C8nGZH1lnIsqcYLTBu6nPMaFlgimjRFCV9kJ3cFY4O1sfZaQg3CFHCSfkoOy4pR4QzepJ9ufYgo7ZD3vlxKDwEHaK0MY9jC16NxqVCrm0uc-NuC20j2KDjNlcr76xWuXK2N1rFPED86ZPYpe20fJw97KUJ8GQ_n2Wf3765vnxfXH18t7y8uCoUxenaitbQtbSBCjU9ZqQBxNOyrnmV5rZlDeo5Jj0ru0rirgJKVAct5xVTFeua6iw73_mOdiO3t9IYsfF6Lf1WYCSmkMSUg5hyEI0oaVK83ik2Y7uGToGNXv5WOanFfMfqlRjcN0EIqnFTJYOXewPvvo4QoljroMAYacGNQeCa0YbVvOH_gVJS14wjltDnO3SQBoS2vUuHqwkXFzSdTEtCpucu_kKl0cFap2ZAr1N9Jng1EyQmwvc4yDEE8eHTcs6-OGBXIE1cBWfGqJ0Nc_DZYYR32f36WAkgO0B5F4KHXigd5eSTrqvN_a1Z_CH7Zy_33Q8JtAN4ceNGb9OHu0_xA4AO-ys |
| CitedBy_id | crossref_primary_10_3389_fimmu_2022_854327 crossref_primary_10_1186_s12961_019_0426_1 crossref_primary_10_3390_tropicalmed5010001 crossref_primary_10_1186_s12913_021_06780_y |
| Cites_doi | 10.1016/S1473-3099(12)70033-6 10.1371/journal.pone.0006914 10.1371/journal.pone.0028066 10.1016/S1473-3099(09)70041-6 10.1111/j.1445-5994.2011.02617.x 10.5588/ijtld.11.0240 10.1056/NEJMoa022928 |
| ContentType | Journal Article |
| Copyright | Armstrong et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated. COPYRIGHT 2014 BioMed Central Ltd. Armstrong et al.; licensee BioMed Central Ltd. 2014 |
| Copyright_xml | – notice: Armstrong et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated. – notice: COPYRIGHT 2014 BioMed Central Ltd. – notice: Armstrong et al.; licensee BioMed Central Ltd. 2014 |
| DBID | C6C AAYXX CITATION NPM KPI 7QL C1K 7X8 5PM ADTOC UNPAY |
| DOI | 10.1186/1752-1505-8-25 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed Gale In Context: Global Issues Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef PubMed Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Bacteriology Abstracts (Microbiology B) MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1752-1505 |
| EndPage | 25 |
| ExternalDocumentID | 10.1186/1752-1505-8-25 PMC4406183 A540652448 25904975 10_1186_1752_1505_8_25 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 29F 2WC 4.4 53G 5GY 5VS 6J9 7X7 7XC 8C1 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACPRK ACUHS ADBBV ADRAZ ADUKV AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AQUVI ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HMCUK HYE IAO IHR IHW ITC KPI KQ8 M0T M48 MK0 M~E O5R O5S OK1 OVT P2P PATMY PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PUEGO PYCSY RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP WOQ ~8M AAYXX CITATION 2VQ ALIPV C1A IPNFZ NPM RIG 7QL C1K 7X8 5PM ADTOC AFFHD UNPAY |
| ID | FETCH-LOGICAL-c5105-c56edb58e308f1748e093086693930bb780f914f72d3a1d3e54cdeb9937c37d83 |
| IEDL.DBID | M48 |
| ISSN | 1752-1505 |
| IngestDate | Wed Oct 29 12:13:08 EDT 2025 Tue Sep 30 16:59:26 EDT 2025 Thu Oct 02 04:15:12 EDT 2025 Tue Oct 07 09:24:23 EDT 2025 Mon Oct 20 22:50:09 EDT 2025 Mon Oct 20 16:57:11 EDT 2025 Thu Oct 16 16:24:38 EDT 2025 Thu May 22 21:23:58 EDT 2025 Mon Jul 21 06:01:34 EDT 2025 Wed Oct 01 03:32:28 EDT 2025 Thu Apr 24 23:03:13 EDT 2025 Sat Sep 06 07:29:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Resource-limited settings Operational research Mobile clinic Internally displaced populations |
| Language | English |
| License | This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5105-c56edb58e308f1748e093086693930bb780f914f72d3a1d3e54cdeb9937c37d83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/1752-1505-8-25 |
| PMID | 25904975 |
| PQID | 1654667907 |
| PQPubID | 23462 |
| PageCount | 1 |
| ParticipantIDs | unpaywall_primary_10_1186_1752_1505_8_25 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4406183 proquest_miscellaneous_1675876989 proquest_miscellaneous_1654667907 gale_infotracmisc_A540652448 gale_infotracacademiconefile_A540652448 gale_incontextgauss_KPI_A540652448 gale_healthsolutions_A540652448 pubmed_primary_25904975 crossref_citationtrail_10_1186_1752_1505_8_25 crossref_primary_10_1186_1752_1505_8_25 springer_journals_10_1186_1752_1505_8_25 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20141201 |
| PublicationDateYYYYMMDD | 2014-12-01 |
| PublicationDate_xml | – month: 12 year: 2014 text: 20141201 day: 1 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Conflict and health |
| PublicationTitleAbbrev | Confl Health |
| PublicationTitleAlternate | Confl Health |
| PublicationYear | 2014 |
| Publisher | BioMed Central BioMed Central Ltd |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd |
| References | C Mitnick (145_CR19) 2003; 348 JC Johnston (145_CR14) 2009; 4 R Guha (145_CR4) 2007; 12 Médecins Sans Frontières and Partners in Health (145_CR20) 2014 Human Rights Watch (HRW) (145_CR2) 2008 World Health Organization (145_CR16) 2009 World Health Organisation (WHO) (145_CR5) 2011 RK Kujur (145_CR1) 2006 EW Orenstein (145_CR15) 2009; 9 P Isaakidis (145_CR6) 2011; 6 Central TB Division (145_CR12) 2014 CN Paramasivan (145_CR10) 2004; 120 145_CR3 145_CR11 S Majumdar (145_CR22) 2011; 41 VK Chadha (145_CR7) 2005; 9 L Shanks (145_CR13) 2012; 16 D Ettehad (145_CR18) 2012; 12 Central TB Division (145_CR21) 2012 Partners in Health, Program in Infectious Disease and Social Change- Harvard Medical School, Division of Social Medicine and Health Inequalities-Brigham and Women’s Hospital (145_CR17) 2003 CN Deivanayagam (145_CR8) 2002; 44 B Mahadev (145_CR9) 2004; 52 19742330 - PLoS One. 2009 Sep 09;4(9):e6914 22373593 - Lancet Infect Dis. 2012 Jun;12(6):449-56 16229217 - Int J Tuberc Lung Dis. 2005 Oct;9(10):1072-82 22145022 - PLoS One. 2011;6(12):e28066 12519922 - N Engl J Med. 2003 Jan 9;348(2):119-28 12437236 - Indian J Chest Dis Allied Sci. 2002 Oct-Dec;44(4):237-42 19246019 - Lancet Infect Dis. 2009 Mar;9(3):153-61 22151949 - Intern Med J. 2011 Dec;41(12):805-8 22565108 - Int J Tuberc Lung Dis. 2012 Aug;16(8):1066-8 15520487 - Indian J Med Res. 2004 Oct;120(4):377-86 |
| References_xml | – volume-title: Left Extremism in India: Naxalite Movement in Chhattisgarh & Orissa. Institute of Peace and Conflict Studies Special Report 25. 2006. Cited 2014 July 22 year: 2006 ident: 145_CR1 – volume-title: The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis year: 2003 ident: 145_CR17 – volume-title: Tuberculosis: Practical Guide for Clinicians, Nurses, Laboratory Technicians and Medical Auxiliaries year: 2014 ident: 145_CR20 – volume: 9 start-page: 1072 year: 2005 ident: 145_CR7 publication-title: Int J Tuberc Lung Dis – ident: 145_CR3 – volume: 12 start-page: 3305 issue: 32 year: 2007 ident: 145_CR4 publication-title: Econ Polit Wkly – volume-title: Global Tuberculosis Control Report 2011 year: 2011 ident: 145_CR5 – volume: 52 start-page: 5 year: 2004 ident: 145_CR9 publication-title: Indian J Tuberc – volume-title: Programmatic Management for Drug-Resistant Tuberculosis Guidelines-May Version year: 2012 ident: 145_CR21 – volume-title: TB India 2014, RNTCP Annual Report: Reach the Unreached-Find, Treat, Cure TB, Save Lives year: 2014 ident: 145_CR12 – volume: 12 start-page: 449 issue: 6 year: 2012 ident: 145_CR18 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(12)70033-6 – volume: 120 start-page: 377 year: 2004 ident: 145_CR10 publication-title: Indian J Med Res – volume: 4 start-page: e6914 issue: 9 year: 2009 ident: 145_CR14 publication-title: PLoS One doi: 10.1371/journal.pone.0006914 – volume-title: Guidelines for Programmatic Management of Drug-Resistant Tuberculosis- Emergency Update 2008 year: 2009 ident: 145_CR16 – volume: 6 start-page: e28066 issue: 12 year: 2011 ident: 145_CR6 publication-title: PLoS One doi: 10.1371/journal.pone.0028066 – volume-title: “Being neutral is our biggest crime”: Government, Vigilante, and Naxalite Abuses in India’s Chhattisgarh State year: 2008 ident: 145_CR2 – volume: 9 start-page: 153 year: 2009 ident: 145_CR15 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(09)70041-6 – volume: 41 start-page: 805 issue: 12 year: 2011 ident: 145_CR22 publication-title: Intern Med J doi: 10.1111/j.1445-5994.2011.02617.x – volume: 44 start-page: 237 year: 2002 ident: 145_CR8 publication-title: Indian J Chest Dis Allied Sci – volume: 16 start-page: 1066 issue: 8 year: 2012 ident: 145_CR13 publication-title: Int J Tuberc Lung Dis doi: 10.5588/ijtld.11.0240 – volume: 348 start-page: 119 issue: 2 year: 2003 ident: 145_CR19 publication-title: N Engl J Med doi: 10.1056/NEJMoa022928 – ident: 145_CR11 – reference: 12437236 - Indian J Chest Dis Allied Sci. 2002 Oct-Dec;44(4):237-42 – reference: 22145022 - PLoS One. 2011;6(12):e28066 – reference: 19742330 - PLoS One. 2009 Sep 09;4(9):e6914 – reference: 16229217 - Int J Tuberc Lung Dis. 2005 Oct;9(10):1072-82 – reference: 22373593 - Lancet Infect Dis. 2012 Jun;12(6):449-56 – reference: 15520487 - Indian J Med Res. 2004 Oct;120(4):377-86 – reference: 22151949 - Intern Med J. 2011 Dec;41(12):805-8 – reference: 22565108 - Int J Tuberc Lung Dis. 2012 Aug;16(8):1066-8 – reference: 19246019 - Lancet Infect Dis. 2009 Mar;9(3):153-61 – reference: 12519922 - N Engl J Med. 2003 Jan 9;348(2):119-28 |
| SSID | ssj0054942 |
| Score | 1.9850615 |
| Snippet | Introduction
The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as... The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as Naxalites. Since... Introduction The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as... Introduction: The eastern part of India has been affected by an ongoing low-intensity conflict between government forces and armed Maoist groups, known as... |
| SourceID | unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 25 |
| SubjectTerms | Analysis Case Study Conflict Studies Emergency Medicine Epidemiology Health aspects Health Promotion and Disease Prevention Health Services Research Medicine Medicine & Public Health Mycobacterium Nurses Public Health Refuse and refuse disposal |
| SummonAdditionalLinks | – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELagSDyEEJQCgQIGIbUXizz8yrGqqFpQEYdWKicrsZ1lpcipNomq_nvGiTfaFBW4JNH6y2rtGXu-Wc-MEfqUmYLGpeBEG80I5bEmBU8FqVImC85MaROfnHz6nR-f068X7CIEyPpcmM39-0Tyz2DdUgKkhREQKLuL7oGB4sOmLD9cr7jg4tA0FGT8852Zwbm57G7YnZsxkdPG6CP0oHeXxfVVUdcbtufoKXoSSCM-GKX8DN2xbhvdPw3b4tvo8fjnGx5zip6jn2cDFXQLbFb9goBH7Vmi63DXl3al-7qBD_DS4QLXzRVZjmHs3TXWY6lcrEOyCG7tEBftsScOVGkHnR99OTs8JuEMBaI9dYIrt6Zk0maxrMD7kDbO4ZHzPIN7WQoZV3lCK5GarEhMZhnVxpaetehMGJm9QFuucfYVwmUhc5aKODfUUJ-0mmTaSMO4qOIcZn6EyHqglQ4Fxv05F7UaHA3JlReM8oJRUqUsQnsT_nIsrXEr8r2XmxpTQ6c5qQ6AbnIGBEVG6OOA8BUtnA-ZWRR926pvP05moL0Aqhr4YboIGQjQPV8Ea4bcnSFhyulZ84e1Ainf5OPUnG36Vg25YVzksfgbBnw04Q_ujNDLUemm_oMzCi6bgB6LmTpOAF8NfN7ilr-GquDUUzOZRWh_rbgqLEftrcO6Pyn2PyTw-v-_9Q16CKSSjiE_u2irW_X2LRC3rnw3zNrfAmM47Q priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pb9MwFLZGdwA08XNAYUBASNvFXZrEP3KsENMGotphlbaTldhOqYicqk00bX89z3ESNUUDDlyaqv4ixfbz8_fS9z0j9ClUSeSnjGKpJMER9SVOaMBwFhCeUKJSPbbi5O9TejqLvl6Syx00bbUwshFDQBjthICjTRl67lQO9hQFvTpeqswtek6PYRcMMJAbgmHiyT20Swlw8wHanU3PJ1e1KrIBNJUbf7-ptzNt--eNDWo7ebL7B_Uhul-ZZXJzneT5xiZ18hgVbfdcbsrPUVWmI3m7Vfnx__X_CXrU8Flv4gzwKdrR5hnacy8DPadxeo6uLmpqauaeWlVzDBG-Za2m9Moq1StZ5QX84C2Ml3h5cY0XLq2-vPGkK93rtc_rrXWdp22xZwZMex_NTr5cfD7FzZkOWFoqB59Uq5RwHfo8g2iIaz-Gr5TGIVzTlHE_i8dRxgIVJmMVahJJpVPLomTIFA9foIEpjH6FvDThMQmYH6tIRVZEOw6l4opQlvkxeKIhwu18CtkUPLfnbuSiDnw4FXbQhB00wUVAhuiwwy9dqY87ke-teQg3Q52PEBOgv5QAYeJD9LFG2AobxqbwzJNqvRbfzs96oMMGlBXwYDJpFBHQPVuUq4c86CHBBche84fWToVtsnlzRhfVWtRaNcpin_0JAzEjsweJDtFLZ9td_yE4hhCSQY9Zz-o7gK1O3m8xix91lfLIUkUeDtFRuz5E4x7Xdw7rUbd-_jIDr_8d-gY9AJIbuRSkAzQoV5V-C0SyTN813uEXMydtBw priority: 102 providerName: Unpaywall |
| Title | Treating drug-resistant tuberculosis in a low-intensity chronic conflict setting in India |
| URI | https://link.springer.com/article/10.1186/1752-1505-8-25 https://www.ncbi.nlm.nih.gov/pubmed/25904975 https://www.proquest.com/docview/1654667907 https://www.proquest.com/docview/1675876989 https://pubmed.ncbi.nlm.nih.gov/PMC4406183 https://conflictandhealth.biomedcentral.com/counter/pdf/10.1186/1752-1505-8-25 |
| UnpaywallVersion | publishedVersion |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: RBZ dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: KQ8 dateStart: 20070101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: DOA dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: ABDBF dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals - Free Access to All customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: DIK dateStart: 20070101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: M~E dateStart: 20070101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: RPM dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: 8C1 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal - Open Access customDbUrl: eissn: 1752-1505 dateEnd: 20250731 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: M48 dateStart: 20070901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: AAJSJ dateStart: 20071201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1752-1505 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0054942 issn: 1752-1505 databaseCode: C6C dateStart: 20070112 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLbY9gAIIe4rjGIQ0vZiSJP4kgeEumrTBlpVTavU8WIlttNVipzRNhr99xwnaVgGA17ci79KtX1OzneSc0HofaDj0Es4I0orSkLmKRIzn5PUpyJmVCem55KTT4bsaBx-mdDJr_inegMXf3TtXD-p8Tz78OP76jMo_KdS4QX7CBbQJ0BsKIFDpxtoC6xU5No4nITNEwVwg8pGOg22LuD4--9bBurmZfqanboZQ9k8SL2P7hb2Ml5dxVl2zVYdPkIPa5KJ-5VUPEZ3jH2CHlR36HCVePQUnZ-VfNFOsZ4XUwJut6OSdomXRWLmqshy-ALPLI5xll-RWRXrvlxhVdXTxarOKMELUwZPO-yxBXl7hsaHB2eDI1I3WiDK8SsYmdEJFSbwRAouijBeBG8ZiwJ4TRIuvDTqhSn3dRD3dGBoqLRJHLVRAdcieI42bW7NNsJJLCLqcy_SoQ5dZmsvUFpoynjqRXB56CCy3l2p6irkrhlGJktvRDDpTkO605BC-rSDdhv8ZVV_41bkG3dYssofbRRX9oGTMgosRnTQuxLhyl5YF1czjYvFQn4dHbdAuzUozeGPqbhOU4DluUpZLeROCwl6qVrTb9dSI92UC2azJi8WskwgYzzy-N8w4Mhx192zg15UktasHzxW8Os4rJi3ZLABuJLh7Rk7uyhLh4eOv4mgg_bW0irXKnfrtu410vyPE3j531v3Ct0D4hlWYUE7aHM5L8xrIHfLpIs2-ITDKAa9LtraPxiOTuHTgA265e2SbqnVMJ7uf4P58XDUP_8JfYZO5Q |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3daxNBEB9qC7YiolVrtNpVhPZl8XJ3-3GPQSxJ2hTBFOrTcre7FwNhU5Icpf-9s_dFr1L1JReyvwvZm4_9TXZmFuBzZNI4yASn2mhGYx5omvJQ0DxkMuXMZLbvi5MnF3x4GY-v2NUWBE0tTJnt3mxJlp66NGvJv-A6F1KkL4yiaNkj2PEJVmiKO4PB-Me48b4Y7sRh3Zzxz7s6i899F3xnDbqfH9lukj6B3cJdp7c36WJxZx06fQ7PagJJBpXEX8CWdfvweFJvke_D0-qPOFLVF72En9OSFroZMatiRjG69ozRbcimyOxKF4slfkDmjqRksbyh8yqlfXNLdNU2l-i6cISsbZkj7bEjh2r1Ci5Pv02_Dml9ngLVnkbhK7cmY9JGgcwxEpE2SPAt50mE1ywTMsiTfpyL0ERp30SWxdrYzDMYHQkjo9ew7ZbOvgGSpTJhoQgSE5vYF7D2I22kYVzkQYJeoAe0edBK183G_ZkXC1UGHZIrLxjlBaOkClkPjlv8ddVm40HkkZebqspEW_tUA6SenCFZkT34VCJ8dwvn02dmabFeq7Pvow7ouAblS_xhOq2rEXB6viFWB3nYQaL56c7wx0aBlB_yOWvOLou1KuvEuEgC8TcMxmvCH-LZg4NK6dr5Y2CK4ZvAGYuOOrYA3xm8O-Lmv8oO4bGnaTLqwUmjuKp2TesHH-tJq9j_kMDb___WI9gdTifn6nx0cfYO9pBsxlUq0CFsb1aFfY-EbpN9qG34N85hQUY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELbGkAYIIRgDCoMZhLS9WEsT_4rEy1SoVsamPWzSeLIS2ymVKrdqE0377znHSbQMDXhJovpLVfvOvu_quzNCnxOT0SgXnGijGaE80iTjsSBFzGTGmcnt0Ccnn57x40v6_YpdbaAvbS5MHe3ebkmGnAZfpcmVh0tThCku-SHYvJgAlWEExMweoIcULJs_v2DER-06DI4PjZsyjX--0zNDdxfjW9bobqRkt136BD2q3DK7uc7m81sWafwcPWuoJD4Ksn-BNqzbRlunzWb5Nnoa_pLDIdPoJfp5URNEN8VmVU0J-NmeO7oSl1VuV7qaL-ADPHM4w_PFNZmF4PbyButQQBfrJoUEr20dLe2xEwcKtoMux98uRsekOVmBaE-o4MqtyZm0SSQL8EmkjVJ45DxN4J7nQkZFOqSFiE2SDU1iGdXG5p7L6EQYmbxCm27h7BuE80ymLBZRaqihPpV1mGgjDeOiiFJYDwaItAOtdFN23J9-MVe1-yG58oJRXjBKqpgN0H6HX4aCG_ci97zcVEgY7WaqOgISyhnQFjlAn2qEr3PhfCDNNKvWa3VyPumB9htQsYAfprMmLwG650tj9ZC7PSRMRN1r_tgqkPJNPnrN2UW1VnXGGBdpJP6GAc9N-OM8B-h1ULqu_-CigiMnoMeip44dwNcI77e42a-6Vjj1hE0mA3TQKq5qFqn1vcN60Cn2PyTw9v-_dQ9tnX8dqx-Ts5N36DGwThpignbRZrmq7HtgdmX-oZ7AvwFNNUQj |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pb9MwFLZGdwA08XNAYUBASNvFXZrEP3KsENMGotphlbaTldhOqYicqk00bX89z3ESNUUDDlyaqv4ixfbz8_fS9z0j9ClUSeSnjGKpJMER9SVOaMBwFhCeUKJSPbbi5O9TejqLvl6Syx00bbUwshFDQBjthICjTRl67lQO9hQFvTpeqswtek6PYRcMMJAbgmHiyT20Swlw8wHanU3PJ1e1KrIBNJUbf7-ptzNt--eNDWo7ebL7B_Uhul-ZZXJzneT5xiZ18hgVbfdcbsrPUVWmI3m7Vfnx__X_CXrU8Flv4gzwKdrR5hnacy8DPadxeo6uLmpqauaeWlVzDBG-Za2m9Moq1StZ5QX84C2Ml3h5cY0XLq2-vPGkK93rtc_rrXWdp22xZwZMex_NTr5cfD7FzZkOWFoqB59Uq5RwHfo8g2iIaz-Gr5TGIVzTlHE_i8dRxgIVJmMVahJJpVPLomTIFA9foIEpjH6FvDThMQmYH6tIRVZEOw6l4opQlvkxeKIhwu18CtkUPLfnbuSiDnw4FXbQhB00wUVAhuiwwy9dqY87ke-teQg3Q52PEBOgv5QAYeJD9LFG2AobxqbwzJNqvRbfzs96oMMGlBXwYDJpFBHQPVuUq4c86CHBBche84fWToVtsnlzRhfVWtRaNcpin_0JAzEjsweJDtFLZ9td_yE4hhCSQY9Zz-o7gK1O3m8xix91lfLIUkUeDtFRuz5E4x7Xdw7rUbd-_jIDr_8d-gY9AJIbuRSkAzQoV5V-C0SyTN813uEXMydtBw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treating+drug-resistant+tuberculosis+in+a+low-intensity+chronic+conflict+setting+in+India&rft.jtitle=Conflict+and+health&rft.au=Armstrong%2C+Edward&rft.au=Das%2C+Mrinalini&rft.au=Mansoor%2C+Homa&rft.au=Babu%2C+Ramesh+B&rft.date=2014-12-01&rft.pub=BioMed+Central+Ltd&rft.issn=1752-1505&rft.eissn=1752-1505&rft.volume=8&rft_id=info:doi/10.1186%2F1752-1505-8-25&rft.externalDocID=A540652448 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1752-1505&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1752-1505&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1752-1505&client=summon |